Evidence map›Paper›PMID 35406550›Full record

ArticleCancers2022

Radiomics-Based Method for Predicting the Glioma Subtype as Defined by Tumor Grade, IDH Mutation, and 1p/19q Codeletion.

Yingping Li, Samy Ammari, Littisha Lawrance, Arnaud Quillent, Tarek Assi, Nathalie Lassau, Emilie Chouzenoux

Abstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. BMC cancer · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. [Prediction of 1p/19q codeletion status in diffuse lower-grade glioma using multimodal MRI radiomics].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yingping LiLaboratoire d'Imagerie Biomédicale Multimodale Paris Saclay, BIOMAPS, UMR1281 Inserm, CEA, CNRS, Université Paris-Saclay, 94805 Villejuif, France.ORCID 0000-0003-4145-8395
Samy AmmariLaboratoire d'Imagerie Biomédicale Multimodale Paris Saclay, BIOMAPS, UMR1281 Inserm, CEA, CNRS, Université Paris-Saclay, 94805 Villejuif, France.ORCID 0000-0002-1506-0714
Littisha LawranceLaboratoire d'Imagerie Biomédicale Multimodale Paris Saclay, BIOMAPS, UMR1281 Inserm, CEA, CNRS, Université Paris-Saclay, 94805 Villejuif, France.ORCID 0000-0002-0838-2053
Arnaud QuillentCentre de Vision Numérique, Institut National de Recherche en Informatique et en Automatique (INRIA), Université Paris-Saclay, 91190 Gif-sur-Yvette, France.ORCID 0000-0001-6358-1293
Tarek AssiDépartement de Médecine Oncologique, Gustave Roussy Cancer Campus Grand Paris, Université Paris-Saclay, 94805 Villejuif, France.
Nathalie LassauLaboratoire d'Imagerie Biomédicale Multimodale Paris Saclay, BIOMAPS, UMR1281 Inserm, CEA, CNRS, Université Paris-Saclay, 94805 Villejuif, France.ORCID 0000-0001-8068-6513
Emilie ChouzenouxCentre de Vision Numérique, Institut National de Recherche en Informatique et en Automatique (INRIA), Université Paris-Saclay, 91190 Gif-sur-Yvette, France.ORCID 0000-0003-3631-6093

Funding

China Scholarship Council 201801810027
6 · The paper itself

Abstract

Gliomas are among the most common types of central nervous system (CNS) tumors. A prompt diagnosis of the glioma subtype is crucial to estimate the prognosis and personalize the treatment strategy. The objective of this study was to develop a radiomics pipeline based on the clinical Magnetic Resonance Imaging (MRI) scans to noninvasively predict the glioma subtype, as defined based on the tumor grade, isocitrate dehydrogenase (IDH) mutation status, and 1p/19q codeletion status. A total of 212 patients from the public retrospective The Cancer Genome Atlas Low Grade Glioma (TCGA-LGG) and The Cancer Genome Atlas Glioblastoma Multiforme (TCGA-GBM) datasets were used for the experiments and analyses. Different settings in the radiomics pipeline were investigated to improve the classification, including the Z-score normalization, the feature extraction strategy, the image filter applied to the MRI images, the introduction of clinical information, ComBat harmonization, the classifier chain strategy, etc. Based on numerous experiments, we finally reached an optimal pipeline for classifying the glioma tumors. We then tested this final radiomics pipeline on the hold-out test data with 51 randomly sampled random seeds for reliable and robust conclusions. The results showed that, after tuning the radiomics pipeline, the mean AUC improved from 0.8935 (±0.0351) to 0.9319 (±0.0386), from 0.8676 (±0.0421) to 0.9283 (±0.0333), and from 0.6473 (±0.1074) to 0.8196 (±0.0702) in the test data for predicting the tumor grade, IDH mutation, and 1p/19q codeletion status, respectively. The mean accuracy for predicting the five glioma subtypes also improved from 0.5772 (±0.0816) to 0.6716 (±0.0655). Finally, we analyzed the characteristics of the radiomic features that best distinguished the glioma grade, the IDH mutation, and the 1p/19q codeletion status, respectively. Apart from the promising prediction of the glioma subtype, this study also provides a better understanding of the radiomics model development and interpretability. The results in this paper are replicable with our python codes publicly available in github.

Indexed as

1p/19q codeletionglioblastomasgliomasIDH mutationradiomicstumor grade

Identifiers

PMID35406550
PMCPMC8997070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.